OHSU

IRB #

IRB00010653

Title

Module Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Principal Investigator

Matthew Taylor

Study Purpose

To learn if TKI258 (the study drug) is safe and has beneficial effects in people who have different types of cancer with pre-identified mutations or translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RET

Medical Condition(s)

Select solid tumors and hematologic malignancies with one of the tumor pathway activations listed above.

Eligibility Criteria

1. Male or female of at least 18 years of age.
2. Diagnosis of select solid tumor (except urothelial tumors, hepatocellular carcinoma, endometrial carcinoma, metastatic breast cancer, squamous NSCLC, or renal cell carcinoma) or hematologic malignancy (except for FLT3 AML and multiple myeloma).
3. Pre-identified FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RET mutation or translocation.
4. Received at least one prior treatment for recurrent, metaastatic, and/or locally advanced disease.
5. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression or development of unacceptable side effects

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Novartis

Recruitment End

12/31/2015

Compensation Provided

No


Go Back